KIT and small cell lung carcinoma: Previous efforts to target c-Kit for therapeutic benefit in c-Kit expressing SCLC have been unsuccessful: in a single arm Phase 2 study, Schneider et al. [20] enrolled 14 patients with c-Kit expressing tumors, of which eight patients with a PR to irinotecan/cisplatin received imatinib maintenance.